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Aim: To examine fracture incidence among participants in the Trial Evaluating Cardiovascular
Outcomes with Sitagliptin (TECOS).
Research design and methods: We used data from 14 671 participants in the TECOS study
who were randomized double-blind to sitagliptin (n = 7332) or placebo (n = 7339). Cumulative
fracture incidence rates were calculated and their association with study treatment assignment
was examined using multivariable Cox proportional hazards regression.
Results: The baseline mean (standard deviation) participant age was 65.5 (8.0) years, diabetes
duration was 11.6 (8.1) years and glycated haemoglobin level was 7.2 (0.5)% [55.2 (5.5) mmol/
mol], and 29.3% of participants were women and 32.1% were non-white. During 43 222
person-years’ follow-up, 375 (2.6%; 8.7 per 1000 person-years) had a fracture; 146 were major
osteoporotic fractures (hip, n = 34; upper extremity, n = 81; and clinical spine, n = 31).
Adjusted analyses showed fracture risk increased independently with older age (P < .001),
female sex (P < .001), white race (P < .001), lower diastolic blood pressure (P < .001) and dia-
betic neuropathy (P = .003). Sitagliptin, compared with placebo, was not associated with a
higher fracture risk [189 vs 186 incident fractures: unadjusted hazard ratio (HR) 1.01, 95% con-
fidence interval (CI) 0.82 to 1.23, P = .944; adjusted HR 1.03, P = .745], major osteoporotic
fractures (P = .673) or hip fractures (P = .761). Insulin therapy was associated with a higher
fracture risk (HR 1.40, 95% CI 1.02-1.91; P = .035), and metformin with a lower risk (HR 0.76,
95% CI 0.59-0.98; P = .035).
Conclusion: Fractures were common among people with diabetes in the TECOS study, but
were not related to sitagliptin therapy. Insulin and metformin treatment were associated with
higher and lower fracture risks, respectively.
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1 | INTRODUCTION
Type 2 diabetes is associated with an elevated risk of fragility frac-
tures, particularly peripheral fractures.1–3 The pathophysiology is
multi-factorial, relating largely to changes in bone quality, which
involves the pathology underlying diabetes complications including
microvascular disease and glycosylation of bone proteins, especially
collagen.4 There are also indirect mechanisms by which diabetes and
its treatments may increase risk of fracture, such as via episodes of
severe hypoglycaemia and/or increased incidence of falls.5,6 As diabe-
tes is associated with a greater fracture risk, it is important to know
whether drugs used to treat diabetes may influence that risk.7,8
In the international Diabetes Outcome Progression Trial (ADOPT),
participants randomized to receive the thiazolidinedione (TZD)
rosiglitazone had a higher incidence of peripheral fractures than
those receiving placebo.9
Incretin hormones [e.g. glucagon-like peptide (GLP)-1 and GLP-2]
have multiple actions on bone, and influence the proliferation of mes-
enchymal progenitor cells. GLP-1 has been reported to induce osteo-
blast differentiation, to inhibit osteoclast activity and to stimulate
bone formation in rodents.4 GLP-2, secreted after food ingestion,
inhibits bone resorption.10 Both GLP-1 and GLP-2 are formed by the
cleavage of the proglucagon molecule, and both are degraded by the
dipeptidyl peptidase-4 (DPP-4) enzyme.11 Because DPP-4 inhibitors
prevent the degradation of incretin hormones, they could be associ-
ated with beneficial effects on the skeleton. A recent meta-analysis
of phase II and III DPP-4 inhibitor trials (28 studies conducted in
20 000 patients) showed a 40% reduction in the risk of fractures
compared with placebo (P = .045); however, that analysis was based
on only 63 fracture events.12 A secondary analysis over 2 years’
follow-up from the placebo-controlled Saxagliptin Assessment of Vas-
cular Outcomes Recorded in Patients with Diabetes Mellitus–
Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial of
saxagliptin (which was not part of the aforementioned DPP-4 inhibi-
tor meta-analysis) showed no association between saxagliptin and
fracture.13 Moreover, a recent large, population-based cohort study
of people with type 2 diabetes found that the new use of sitagliptin
was not associated with increased risk of fracture compared with
non-users,14 consistent with two other studies.15,16
In the present study, we performed a prespecified exploratory
intention-to-treat analysis of fracture data from the Trial Evaluating
Cardiovascular Outcomes with Sitagliptin (TECOS), which was a large,
global, prospective controlled trial of 14 735 participants randomized
to receive the DPP-4 inhibitor sitagliptin or placebo.
2 | RESEARCH DESIGN AND METHODS
2.1 | Trial overview
The design, rationale and main results of TECOS have been published
in detail elsewhere.17,18 Briefly, 14 735 participants from 38 countries
were randomized between December 2008 and July 2012. Eligible par-
ticipants were aged ≥50 years with type 2 diabetes, cardiovascular dis-
ease, and glycated haemoglobin (HbA1c) values of 6.5% to 8.0% (48-
64 mmol/mol) on stable-dose mono- or combination therapy with met-
formin, pioglitazone or sulphonylurea, or insulin with or without met-
formin. Study participants were randomized (1:1) in a double-blind
fashion to either sitagliptin or placebo at dosing appropriate for their
estimated glomerular filtration rate (eGFR). Patients with an eGFR
<30 mL/min per 1.73 m2 were not eligible for enrolment. Treatment
for diabetes and its comorbidities was provided by usual care providers
based on local guidelines. The addition of any antihyperglycaemic
agent, other than a GLP-1 receptor agonist or open-label DPP-4 inhibi-
tor, was permitted, although use of rosiglitazone was discouraged. Data
regarding the use of concomitant medications, occurrence of severe
hypoglycaemia (hypoglycaemia requiring the assistance of another indi-
vidual), death, hospitalization, cardiovascular events and interventions,
diabetes complications, fractures, serious adverse events and adverse
events resulting in study drug discontinuation were recorded at partici-
pant visits. An independent clinical events classification committee
whose members were unaware of treatment assignments adjudicated
all events of death, myocardial infarction, stroke, hospitalization for
unstable angina or heart failure, acute pancreatitis and cancer. Adjudi-
cated event definitions have been published previously.18 TECOS was
designed and run by the Duke Clinical Research Institute (DCRI) and
the University of Oxford Diabetes Trials Unit, in an academically inde-
pendent collaboration with the sponsor, Merck Sharp & Dohme Corp.
The database was held at and independently verified by the DCRI. The
protocol was approved by the ethics committees associated with all
participating trial sites, and all participants provided written informed
consent for trial participation. The trial was registered at ClinicalTrials.
gov under the number NCT00790205.
2.2 | Main trial results
There were 14 671 participants included in the intention-to-treat pop-
ulation with a median (interquartile range; maximum) follow-up of 3.0
(2.3-3.8; 5.7) years. Overall, 95.1% of participants allocated to sitaglip-
tin and 94.1% allocated to placebo completed the study, with prema-
ture study medication discontinuation occurring in 26.1% and 27.5%
of participants, respectively. Vital status was determined at study end
for 97.5% of participants. The TECOS study showed sitagliptin to be
non-inferior to placebo with respect to the primary composite end-
point of cardiovascular death, non-fatal myocardial infarction, non-fatal
stroke, or hospitalization for unstable angina [hazard ratio (HR) 0.98,
95% confidence interval (CI) 0.88 to 1.09; P < .001 for non-inferiority].
Random allocation was successful, and there were no clinically impor-
tant, statistically significant differences between patients allocated to
sitagliptin compared with patients allocated to placebo.
2.3 | Fracture-related outcomes
The primary outcome for this analysis was “any post-randomization
incident fracture.” Fracture data were collected prospectively using
two complementary methods of ascertainment: first, as serious
adverse events (typically these were events requiring hospitalization,
such as a hip fracture or proximal humeral fracture requiring surgical
fixation) that were captured using standard serious adverse event
recording methods,17,18 and second, via an electronic case report
form fracture questionnaire (Appendix S1) completed at follow-up
visits by study personnel, when the presence and location of frac-
tures were collected from patients. Information was ascertained
regarding confirmation by a clinician and/or whether radiograph veri-
fication of the fracture had been performed. We combined these
events and hereafter refer to them as “any fracture.” Secondary end-
points included major osteoporotic fractures (i.e. of the hip, clinical
spine, proximal humerus or distal radius).
2.4 | Other measurements
Detailed sociodemographic, clinical, laboratory and medication-
related information was collected at the time of study enrolment. We
did not have all of the variables necessary to calculate fracture risk
according to the World Health Organization FRAX tool (without bone
mineral density data) or other tools, such as parental history of hip
fracture or pre-randomization history of fragility fracture, but we did
have data on age, sex, race, body mass index, chronic kidney disease,
smoking status, antidiabetic medications (sitagliptin, metformin, sul-
phonylureas, thiazolidenediones and insulin) and cardiovascular
medications.
TABLE 1 Selected baseline demographic, clinical and laboratory characteristics and baseline diabetes and cardiovascular related treatments:
overall and according to the presence or absence of incident fracture
All No fracture Fracture
P(N = 14 671) (n = 14 296) (n = 375)
Age, years 65.5 (8.0) 65.4 (8.0) 68.2 (7.9) <.001
Age ≥ 65 years 7735 (53.9) 7485 (53.5) 250 (67.6) <.001
Age ≥ 75 years 2004 (14.0) 1920 (13.7) 84 (22.7) <.001
Female sex 4297 (29.3) 4130 (28.9) 167 (44.5) <.001
White race 9957 (67.9) 9662 (67.6) 295 (78.7) <.001
Duration of diabetes, years 11.6 (8.1) 11.5 (8.1) 13.7 (9.1) <.001
Duration of diabetes ≥10 years 7611 (51.9) 7377 (51.6) 234 (62.4) <.001
Qualifying HbA1c, % 7.2 (0.5) 7.2 (0.5) 7.2 (0.5) .141
Qualifying HbA1c, mmol/mol 55.2 (5.5) 55.2 (5.5) 55.2 (5.5) .141
Body mass index, kg/m2 30.2 (5.6) 30.2 (5.6) 30.5 (5.8) .374
Systolic blood pressure, mm Hg 135.0 (17.0) 135.1 (17.0) 133.4 (16.5) .070
Systolic blood pressure ≥135 mm Hg 7074 (48.4) 6907 (48.5) 167 (44.7) .147
Diastolic blood pressure, mm Hg 77.2 (10.5) 77.3 (10.4) 74.1 (11.5) <.001
Diastolic blood pressure <80 mm Hg 7369 (50.4) 7131 (50.0) 238 (63.6) <.001
eGFR, mL/min/1.73 m2 1 74.9 (21.1) 74.9 (21.0) 71.9 (22.9) .006
eGFR <50 mL/min/1.73 m2 1 1369 (9.3) 1317 (9.2) 52 (14.0) .002
LDL cholesterol, mmol/L 2.35 (1.49) 2.36 (1.51) 2.22 (0.88) .127
Previous cardiovascular disease 10 863 (74.0) 10 593 (74.1) 270 (72.0) .360
Previous myocardial infarction 6255 (42.6) 6103 (42.7) 152 (40.5) .404
Previous PCI 5714 (39.5) 5562 (39.4) 152 (41.3) .472
Previous CABG 3664 (25.0) 3571 (25.0) 93 (24.8) .937
Previous cerebrovascular disease 3588 (24.5) 3478 (24.3) 110 (29.3) .026
Previous peripheral arterial disease 2433 (16.6) 2367 (16.6) 66 (17.6) .592
Previous congestive heart failure 2643 (18.0) 2580 (18.0) 63 (16.8) .535
Current smoker 1678 (11.4) 1636 (11.4) 42 (11.2) .884
Diabetic neuropathy 3354 (22.9) 3235 (22.6) 119 (31.7) <.001
Metformin 11 966 (81.6) 11 689 (81.8) 277 (73.9) <.001
Sulphonylurea 6645 (45.3) 6492 (45.4) 153 (40.8) .077
TZD 396 (2.7) 377 (2.6) 19 (5.1) .004
Insulin 3408 (23.2) 3290 (23.0) 118 (31.5) <.001
More than one of the agents above 8820 (60.1) 8604 (60.2) 216 (57.6) .313
β blocker 9322 (63.5) 9087 (63.6) 235 (62.7) .722
ACE inhibitor or ARB 11 555 (78.8) 11 267 (78.8) 288 (76.8) .347
Calcium channel blocker 4961 (33.8) 4835 (33.8) 126 (33.6) .929
Non thiazide diuretic 2556 (17.4) 2482 (17.4) 74 (19.7) .232
Thiazide diuretic 3464 (57.5) 3369 (57.6) 95 (56.2) .723
Aspirin 11 518 (78.5) 11 223 (78.5) 295 (78.7) .940
Statin 11719 (79.9) 11 423 (79.9) 296 (78.9) .644
Ezetimibe 761 (5.2) 742 (5.2) 19 (5.1) .915
Nitrates 2813 (19.2) 2742 (19.2) 71 (18.9) .905
Continuous variables are mean (standard deviation), and categorical variables are n (%).
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CABG, coronary artery bypass graft; PCI, percutaneous coronary
intervention.
1 Modification of Diet in Renal Disease formula used to calculate eGFR. Site-reported values are presented.
2.5 | Statistical analysis
Details on the randomization performed in the present study have
been published.18 We undertook several prespecified analytical steps
(all analyses were performed on the intention-to-treat population).
First, we reported the number and frequency of fractures over the
duration of study follow-up and calculated the incidence rate in terms
of fractures per 1000 person-years of follow-up. If a patient had
more than one fracture, we only considered the first event. Second,
we used Kaplan–Meier survival analysis to plot the cumulative esti-
mated incidence of fracture according to treatment assignment, and
then tested for differences between sitagliptin and placebo using the
log-rank test. Third, exploratory analyses were used to describe the
baseline characteristics for the overall study cohort and for those
with versus those without incident fracture, and differences were
tested using chi-squared tests or Student’s t-tests, as appropriate.
A multivariable model was then developed to assess the inde-
pendent association between assigned study treatment (sitagliptin vs
placebo) and time to first fracture; the models were adjusted for
other potentially important baseline factors using Cox proportional
hazards regression. Sociodemographic, clinical or medication-related
variables were included based on clinical (literature review, expert
opinion) and statistical significance (univariate tests with P value
<.10; Table 1); no automated covariate selection procedures were
used. Linearity of the effect of continuous covariates in these models
was verified using restricted cubic spline functions with five knots.
Results of the final model are shown in Table 2, and an identical ana-
lytical approach was applied to generate the results shown in
Figure 1. All first-order interactions with the study treatment assign-
ment were tested; none achieved nominal statistical significance
(P < .10), and none were included in the final multivariable model.
We used visual inspection of log-minus-log plots to determine
whether there were any violations of the proportional hazards
assumptions; none were detected. Estimates of associations with
time to fracture are reported as HRs and 95% CIs.
We then undertook three sensitivity analyses. First, we examined
the association of the study treatment assignment with (1) major
osteoporotic fractures and (2) hip fractures as the dependent variable
of interest rather than any incident fracture. Second, because of the
well-known strong association of older age with fracture, we
repeated analyses restricted to those aged ≥75 years, as well as those
aged ≥65 years. Third, we included one additional covariate defined
as “any post-randomization severe hypoglycaemic event” in the multi-
variable adjustment model to assess whether hypoglycaemia may
have contributed to the fracture risk.
Unless otherwise defined, we considered a two-sided P value of <.05
to be statistically significant, and did not correct for multiple testing. SAS
version 9.4 (Cary, North Carolina) was used for all statistical analyses.
3 | RESULTS
The mean (standard deviation) participant age was 65.5 (8.0) years,
diabetes duration was 11.6 (8.1) years, and HbA1c was 7.2 (0.5)%
[55.2 (5.5) mmol/mol]; 29.3% were women, 32.1% were non-white,
11.4% still smoked, and 22.6% reported diabetic neuropathy as a com-
plication. Over a median (interquartile range) 3.0 (2.3-3.8) years of
follow-up, 3.9% of participants had a non-fatal myocardial infarction,
2.1% had a non-fatal stroke, 3.1% were hospitalized for heart failure,
and 7.5% died. The baseline characteristics according to the presence
or absence of incident fractures during the study are shown in Table 1.
3.1 | Incidence of fractures
During 43 222 person-years of follow-up, 375 participants (2.6%)
had a fracture, giving an overall incidence rate of 8.7 per 1000
person-years. Of these fractures, 146 were major osteoporotic frac-
tures (3.4 per 1000 person-years) and 34 were hip fractures (0.8 per
1000 person-years). Lower extremity fractures were the most com-
monly reported fractures (n = 102, 2.4 per 1000 person-years;
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A: Adjusted for age, sex, white race, diastolic blood pressure, current smoker, diabetes duration, 
diabetic neuropathy, and use of metformin, sulfonylurea, TZD, and insulin.   
FIGURE 1 Sensitivity analyses comparing
the outcomes of any fracture versus major
osteoporotic fracture versus hip fracture
according to treatment assignment
(sitagliptin vs placebo).
Figure 2). Those with an incident fracture were older and more likely
to be female, to be white, to have a longer diabetes duration, and to
have complications of diabetes and other comorbidities (Table 1). Of
the 375 incident fractures, 132 (35%) were ascertained (and thereaf-
ter confirmed by providers and radiographs) via the trial’s routine
adverse event reporting system, and an additional 243 (65%) frac-
tures were ascertained using the supplemental fracture survey of
patients. Of the 243 fractures documented by survey, 91% were con-
firmed by providers, 83% were confirmed by radiographs, and 82%
had confirmation by both providers and radiographs. Although the
assigned study treatment was not associated with the hazard of frac-
ture, older age, female sex, white race, lower diastolic blood pressure
and diabetic neuropathy were each associated independently with an
increased fracture risk in the adjustment model (Table 2).
3.2 | Association of diabetes treatments
and fractures
The majority of participants were taking metformin (81.6%) at baseline,
and 60.1% were taking two or more antidiabetic treatments (Table 1).
After adjustment for sociodemographic and clinical factors, insulin ther-
apy was associated with increased risk of fracture [adjusted HR 1.40
(95% CI 1.02-1.91); P = .035]; conversely, metformin use was signifi-
cantly associated with a decreased risk of fracture [adjusted HR 0.76
(95% CI 0.59-0.98); P = .035]. TZD therapy was not associated with a
significantly increased risk in adjusted analyses, but the CIs for this
were wide, probably related to the low overall TZD usage in the trial
[adjusted HR 1.54 (95% CI 0.94-2.52); P = .087].
3.3 | Association of sitagliptin and fractures
There were 189 incident fractures (8.7 per 1000 person-years) with
sitagliptin compared with 186 fractures (8.6 per 1000 person-years)
with placebo [unadjusted HR 1.01 (95% CI 0.82-1.23); P = .944] and
curves of estimated cumulative fracture incidence essentially over-
lapped for the duration of the trial (Figure 3). Also, there was no sig-
nificant association (in adjusted analyses) between assigned sitagliptin
use and any incident fracture (P = .745) or major osteoporotic
(P = .673) or hip fracture (P = .761; Figure 1).
3.4 | Additional exploratory sensitivity analyses
There were more fractures in the elderly participants, in both abso-
lute and relative terms, in the present study. Just over half (53.9%) of
Sitagliptin Placebo
UPPER EXTREMITY 43 (0.6%) 38 (0.5%)
Upper arm 14 17
Lower arm 16 12
Wrist 13   9
Sitagliptin Placebo




HIP / UPPER LEG 26 (0.4%) 27 (0.4%)
Hip 18 16
Upper leg   8 11
Sitagliptin Placebo
LOWER LEG / 
ANKLE / FOOT 52 (0.7%) 50 (0.7%)
Lower leg 18 11
Ankle 14 12
Foot 20 27
FIGURE 2 Frequency and location of incident fractures according to treatment assignment (sitagliptin vs placebo). Face, hand and other
fractures excluded.
TABLE 2 Association between assigned study treatment and time to













TZD therapy at randomization 1.54 (0.94-2.52) .087
Insulin therapy at randomization 1.40 (1.02-1.91) .035
Age (per year increase) 1.03 (1.02-1.05) <.001
Female 1.95 (1.58-2.40) <.001
White race 1.58 (1.23-2.04) <.001
Current smoker 1.16 (0.83-1.62) .399
Duration of diabetes ≥10 years 1.25 (0.98-1.57) .068
Diastolic blood pressure <80 mm
Hg
1.50 (1.21-1.86) <.001
Diabetic neuropathy 1.42 (1.12-1.76) .003
the participants were aged ≥65 years, and 14% were aged ≥75 years
[HR adjusted for age ≥65 vs <65 years 1.50 (95% CI 1.20-1.88),
P = .001; HR adjusted for age ≥75 vs <75 years 1.55 (95% CI 1.21-
1.99), P = .001]. For both age thresholds, fractures were balanced
between sitagliptin and placebo. There were 129/3859 fractures
(3.3%) in participants aged ≥65 years taking sitagliptin (5.8 per 1000
person-years) and 121/3876 (3.1%) in participants aged ≥65 years on
placebo (5.4 per 1000 person-years) for an adjusted HR of 1.07 (95%
CI 0.84-1.38; P = .574). There were 44/970 fractures (4.5%) in parti-
cipants aged ≥75 years taking sitagliptin (16.9 per 1000 person-years)
and 40/1034 (3.9%) in participants aged ≥75 years on placebo (14.3
per 1000 person-years) for an adjusted HR of 1.25 (95% CI 0.81-
1.92; P = .319).
Finally, after randomization, severe hypoglycaemic events were
not uncommon, although there was no difference between sitagliptin
and placebo [2.2% vs 1.9%; HR 1.12 (95% CI 0.89-1.40); P = .330]. In
a sensitivity analysis, any severe hypoglycaemic event was independ-
ently associated with an increased risk of fracture [adjusted HR 1.85
(95% CI 1.14-2.99); P = .012].
4 | DISCUSSION
Among the complications associated with diabetes, fractures have been
neglected despite an increased risk of 20% to 30% compared with
patients without diabetes.3,19 In TECOS, fractures occurred at a rate of
nine per 1000 person-years. Hence, the skeletal safety profiles of dia-
betic medications deserve attention. In this large, prospective, ran-
domized, placebo-controlled trial of sitagliptin in patients with type
2 diabetes, we showed the following: fractures were common in this
population; sitagliptin was not associated with a greater fracture risk;
and metformin therapy was associated with a lower fracture risk, whilst
insulin therapy was associated with a higher fracture risk.
It is difficult to assess fracture risk in people with type 2 diabetes,
both in clinical trials and in practice. Bone mineral density is often
not significantly lower in people with type 2 diabetes, and
measurement of bone density in such people may not provide as use-
ful an estimate of fracture risk as in those without diabetes.20 Type
2 diabetes has not yet been incorporated into the FRAX fracture risk
assessment tool to try and improve its fracture risk prediction capa-
bility.21 Bone strength encompasses both bone quantity and bone
quality, and it is particularly the latter that is thought to be compro-
mised in people with diabetes. Some newer techniques such as tra-
becular bone score, a textural measurement derived from bone
mineral density, may be more helpful in assessing fracture risk.22,23
There have been many preclinical and clinical studies looking at
the effects of different antidiabetic agents on skeletal health.4,7,8,24
Metformin, the most commonly used antidiabetic agent, either has a
neutral or minor beneficial effect on bone mineral density and frac-
ture risk, as demonstrated in this study, which is consistent with the
Rochester population-based study25; however, as with other drugs,
data are somewhat conflicting and incomplete. Similarly, on the basis
of preclinical studies with incretins and DPP-4 inhibitors, it might be
surmised that the incretin hormones would have beneficial effects on
bone. This speculation was assessed in a recent meta-analysis of
16 randomized controlled trials with incretin agents whose results
were generally neutral but included some divergent results depending
on the GLP-1 receptor analogue used. The studies were, however,
not designed as primary fracture outcome studies, so these conflict-
ing results must be interpreted with caution.26,27 Nevertheless, we
believe that the totality of randomized and non-randomized evidence
(including the present study) strongly suggests that the DPP-4 inhibi-
tor class of agents has no clinically important effect on bone or the
risk of fracture.
The increased risk of fracture associated with insulin is notewor-
thy and has been reported previously.4,7,13,25 The pathophysiology as
to why exogenous insulin might increase fracture risk is not well
understood. From animal studies and assessment in type 1 diabetes,
insulin is thought to be osteoanabolic.28 The situation in type 2 diabe-
tes is more controversial and hampered by the lack of randomized
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FIGURE 3 Kaplan–Meier estimated
cumulative incidence of any fracture
according to treatment assignment
(sitagliptin vs placebo).
of insulin in type 2 diabetes may be a marker of more severe disease
and the presence of more severe complications or an indication of a
greater proclivity to symptomatic hypoglycaemia and falls.29 Previous
studies have shown that falls are more common in patients with type
2 diabetes receiving insulin therapy and with lower HbA1c
levels.30–32 Even after correcting for falls, however, in these studies
fracture risk remains increased.5,33–36 In a recent analysis from the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial,
severe hypoglycaemia has been associated with falls and with frac-
tures, in models adjusted for age, sex, race, treatment assignments
and baseline HbA1c (unpublished data).
The present study supports both direct and indirect effects of
insulin on fracture. In TECOS, where 2.2% of participants on sitaglip-
tin and 1.9% on placebo experienced severe hypoglycaemia after ran-
domization, there was also a significant association with fractures.
Also, participants who experienced a fracture were more likely to
have more advanced diabetes, as defined by the presence of compli-
cations (e.g. neuropathy), and to have more risk factors for falls
(e.g. lower blood pressure). Even accounting for these factors in care-
ful multivariable adjustment, insulin treatment remained associated
with a higher risk of fracture, although the potential for residual con-
founding remains with any analysis of a non-randomized treatment.
The pathophysiology relating diabetes, bone health and fracture is
complex, and while an increased risk of injurious falls is probably an
important (although not the only) contributor, the present findings
suggest that some diabetes treatments have little or no effect on
fracture, while other agents can directly or indirectly increase the risk.
Clearly, this is an area that requires further investigation.
The present large prospective randomized controlled trial over-
comes many of the problems inherent in observational studies, and
provides a relatively homogenous population with detailed clinical
information at baseline; however, it was powered for cardiovascular
safety and not fracture risk, and any conclusions related to non-
randomized treatment assignments (e.g. analysis of risk associated
with severe hypoglycaemic events) or post-randomization covariates
are subject to the limitations of all observational studies. In addition,
there were some design-specific limitations of our study.
First, with the methodology used, we were able to capture most
symptomatic fractures, and self-report of recent fractures is valid and
both very sensitive and specific33,34; however, certain fractures may
have been missed, and we may have underestimated the overall frac-
ture incidence. In general, only ~25% of vertebral fractures are clini-
cally apparent at the time of their occurrence—the majority are silent
or occult37—but there is no reason to believe that the incidence of
these fractures would differ according to antidiabetic treatments.
Previous studies have shown that most fractures in people with type
2 diabetes are peripheral in location, and this is consistent with our
findings (Figure 2).
Second, diabetes control in the population was reasonable, with
mean baseline HbA1c of 7.2 (0.5)% [55.2 (5.5) mmol/mol], which was
maintained fairly evenly throughout the study. Since glycaemic equi-
poise was achieved, we could not assess participants with very high
or very low HbA1c level, nor could we examine the role of exces-
sively rapid changes in glycaemic control. We did examine post-
randomization severe hypoglycaemic events as part of a prespecified
analysis related to diabetes control. Beyond this one analysis, similar
to that performed by others,13 we have refrained from an excessive
number of speculative post hoc examinations of our data.
Third, we did not examine post-randomization risk factors for
falls, such as new use of sedative-hypnotics, new initiations of antihy-
pertensive agents, or new diagnoses of Parkinson’s disease or stroke,
and we did not have information related to the mechanisms of injury,
such as whether fractures were low trauma. By the same token, we
examined only baseline treatments and not post-randomization
changes in doses, changes of regimen or medication adherence.
Last, the present study cannot provide insight into mechanism(s).
We do not have detailed histories related to falls, bone mineral den-
sity tests, markers of bone turnover, or measures of “bone quality”
based on biopsy or trabecular bone score. Our intent was to describe
the rates and risk factors for fracture and the role of a randomized
treatment versus placebo, and not to investigate the underlying
pathophysiology.
In summary, the TECOS randomized study of the DPP-4 inhibitor
sitagliptin, for which cardiovascular safety had already been demon-
strated, found no increase in risk of fractures compared with placebo.
We confirmed that several well-known clinical risk factors for frac-
tures also increase risk in those with diabetes, and showed that risk
factors for falls such as hypoglycaemia or hypotension predispose to
fracture. However, we also found that insulin was associated with
increased risk of fracture while metformin was associated with a
decreased fracture risk. In contrast, sitagliptin was not associated
with either an increased or decreased fracture risk. Because diabetes
and osteoporosis and fractures are common chronic conditions, espe-
cially in the elderly, bone health should be considered an important
aspect of diabetes care. The findings from the present study may
increase awareness of this confluence of potentially preventable
adverse events and help inform clinicians regarding the selection of
diabetes treatments in people at high risk of fracture.
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